Premium – Page 9 – Endpoints News

SIGN UP

Genentech team does some cutting-edge work on a new class of antibiotics — here's why that's important

3 years ago

The high-roller club in biopharma: Who’s paying top-dollar for upfronts? And who are the busiest players at the deal table?

3 years ago

Who are the most productive drug developers in biopharma? Our top-20 list has lots of surprises

3 years ago

Top 10 pipeline blowups, setbacks and snafus in H1 2018

3 years ago

Vant commander Ramaswamy heads back to Nasdaq with a $150M pitch — are investors ready to forgive Axovant?

3 years ago

12 top China VCs you need to know who are making a transpacific splash (Part 2)

3 years ago

RIP XTuit: Great brains, hot target and vet CEO Deborah Dunsire in charge couldn’t stop this biotech from going down

3 years ago

What you need to know about this record-setting biotech IPO burst as 5 more crash the party looking for $547M

3 years ago

The 2-trial hurdle for drug approvals is steadily losing ground. Are we devaluing the industry's R&D gold standard?

4 years ago

Where does the science come from? The top 20 NIH-funded institutions in 2017

4 years ago

The good, the bad and the ugly for the top 15 spenders in the global drug R&D business: 2018

4 years ago

Bristol-Myers offers some eagerly awaited Checkmate-227 results, but they're not changing medical practice -- yet

4 years ago

What are the top 10 corporate VCs in biopharma today? And what do they want to fund — or steer clear of?

4 years ago

Where the money is: Top 100 VCs investing in US biotechs during 2017

4 years ago

The class of 2017's winners and losers: A year of 'nonstop scientific achievements' raises troubling issues

4 years ago

Biopharma's top 10 overseas cash hoards. And what kind of M&A spree would $171B buy?

4 years ago

The top 10 hit parade of biopharma licensing deals for 2014-2017

4 years ago

Who are the top 10 players that dominate the cancer drug market? And who's growing fastest?

4 years ago

Insiders: The top 20 rare disease specialists spotlight key biotech trends behind the boom

4 years ago

R&D trend #5: The top execs in biotech are riding a boom — but there’s one big step left

4 years ago

Top trend #4: We’re coming to a tipping point on cancer R&D, and it may not be pretty

4 years ago

The top 5 trends in biotech - #3: High valuations for attractive biotechs are a durable symptom of a thriving financing arena

4 years ago

How Enterprise customers can get Endpoints News into their Slack

4 years ago

Publisher's note

Top 5 biopharma trends: The long-awaited biopharma revolution in China has arrived — don’t lose out

4 years ago

First page Previous page 6 7 8910 Next page Last page